Benjamin Ebert became CEO of Dana-Farber Cancer Institute at an inflection point in late 2024, helming the organization in the midst of building a massive $1.6 billion cancer hospital, and winding down its partnership with Brigham and Women’s Hospital to instead pair up with Beth Israel Lahey Health.
The wheels of change were set in motion by his predecessor, Laurie Glimcher, who led Dana-Farber from 2016 to 2024. But Ebert, a medical oncologist who previously served as chair of the department of medical oncology at the institute for seven years, has no shortage of ideas and vision for Dana-Farber’s future. He recently detailed them to the Globe. This conversation has been edited for length and clarity.
You’ve embarked on this huge project set up by your predecessor. While things are coming together, it seems there’s still so much to do.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
